Neurizon Therapeutics (ASX): Sergio Duchini & Dan O'Connell on NUZ-001, HEALEY Phase 2/3 & ALS
Neurizon Therapeutics (ASX) is approaching a critical period in the development of NUZ-001 for amyotrophic lateral sclerosis (ALS), the most common form of motor neuron disease (MND). In this episode of the Homodeus Research Podcast, Interim Executive Chair Sergio Duchini and CFO Dan O'Connell discuss the completion of recruitment into Neurizon's Phase 2/3 HEALEY ALS Platform Trial, with 250 participants recruited across the United States. The conversation explores why Neurizon chose the HEALEY platform, the encouraging survival signal observed in the earlier Phase 1 MEND study, the trial's…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.